A Clinical Study On Shenkang Injection Combined With High Does Atorvasatin To Preventing Contrast-induced Nephropathy After Percutaneous Coronary Intervention

Objective Research Shenkang injection combined with high does Atorvasatin in patients Integrative prevent contrast-induced nephropathy after percutaneous coronary intervention may occur, which evaluate the effectiveness of the two drugs in combination in the prevention of contrast-induced nephropathy after percutaneous coronary intervention and security to improve the efficacy of clinical preventive treatment of CINMethods Select September 2014-January 2015 Department of Cardiology hospitalized cases and 90 cases undergoing coronary intervention in the Affiliated Hospital of Chengdu University of TCM (Traditional Chinese Medicine Hospital, Sichuan Province); by randomly divided into the experimental group (Shenkang injection combined with high-dose atorvastatin group,30 cases) and the control group (high-dose atorvastatin group,30 cases) and the blank group (water-based group,30 cases), the course are scheduled for surgery and surgery before after three days.Observed incidence of contrast-induced nephropathy, as well as preoperative and postoperative 24 hours,48 hours,72 hours, serum creatinine (Scr) 7 days, blood urea nitrogen (BUN), glomerular filtration rate (eGFR) monitoring while observing the course of medication side effects.Results 1 Efficacy Evaluation:Clinical trials to complete a total of 78 cases, the results show that:The end of the event rate assessment:the experimental group 29 cases, the end of the event was 3.33%; the control group,29 cases, the end of the event was 10.34%; the blank group of 30 patients, end event rate of 30.00%in the control group and the the blank group, the experimental group and the control group pairwise comparison the difference was not statistically significant (P> 0.05); the experimental group and the blank group pairwise comparison the difference was statistically significant (P<0.05). Patients were compared with preoperative three groups 24h,48h,72h, compared with preoperative Scr, BUN were increased, GFR lower (P<005), among the three groups at each time point Scr, BUN, GFR level was not having statistically significant (P> 0.05), but among the three groups for the growth rate of creatinine (AScr), BUN growth rate (ABUN) and GFR decrease in amplitude (AGFR) difference was statistically significant (P<0.05). Patients in the experimental group decreased 7 days Scr, BUN decreased, GFR increases were statistically significant (P<0.05) compared with the preoperative.2. Safety Evaluation:Three groups of patients during clinical studies showed no abnormal safety testing, and drug-related adverse events occurred.ConclusionShenkang injection combined with high does Atorvasatin in addition to reduce the incidence of contrast-induced nephropathy after percutaneous coronary intervention, but also to improve the adverse effects of contrast media on renal function, a low incidence of adverse reactions, good safety.